Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 12
Phase 23

Trial Status

Completed6

Role Distribution

Other Roles6

Activity Timeline

Clinical Trials (6)

NCT06947304Phase 1Completed
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)+1 more
StudydirectorStart date: 2025-08-22
NCT06108219Phase 2Completed
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Metabolic Dysfunction-associated Steatohepatitis (MASH)Nonalcoholic Steatohepatitis (NASH)
StudydirectorStart date: 2023-10-25

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Nezam Afdhal, MD

Beth Israel Deaconess Medical Center

Related
5 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Similarity Score15%

Ming-Shiang Wu, MD, PhD

National Taiwan University Hospital

Related
7 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Similarity Score15%

Yaron Rotman, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Related
7 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Similarity Score15%

Michael Roden, Prof., MD

German Diabetes Center

Related
16 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Similarity Score15%

Stephen A. Harrison, MD

Brooke Army Medical Center

Related
16 trials

Shared therapeutic areas:

Nonalcoholic SteatohepatitisNon-alcoholic Fatty Liver Disease
Similarity Score15%

Marc G Ghany, M.D.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Related
14 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
Similarity Score15%

Salomé Pérez

University of Navarra

Related
3 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver Disease
Similarity Score8%

Ali MA Ismail, lecturer

Cairo University

Related
27 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver Disease
Similarity Score8%

Sonia Caprio, MD

Yale University

Related
9 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver Disease
Similarity Score8%

Geert Robaeys, prof. dr.

Hasselt University

Related
6 trials

Shared therapeutic areas:

Non-alcoholic Fatty Liver Disease
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (6)

Showing 6 of 6 trials

NCT06947304Phase 1StudyDirector

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)+1 more
Completed
NCT06108219Phase 2StudyDirector

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Metabolic Dysfunction-associated Steatohepatitis (MASH)Nonalcoholic Steatohepatitis (NASH)
Completed
NCT05320146StudyDirector

A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)
Completed
NCT05117489Phase 1StudyDirector

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)
Completed
NCT04524403Phase 2StudyDirector

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Antipsychotic-induced Weight Gain (AIWG)
Completed
NCT03818256Phase 2StudyDirector

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Antipsychotic-induced Weight Gain (AIWG)
Completed

All 6 trials loaded